DBV Technologies to Attend Upcoming Investor Conferences
(Thomson Reuters ONE) -
Press Release
Montrouge, France, November 10, 2016
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), today announced that members of its management team will present and host
investor meetings at the following upcoming investor events:
Pierre-Henri Benhamou, Chairman & Chief Executive Officer, David Schilansky,
Chief Operating Officer, and Susanna Mesa, Senior Vice President, Strategy, will
present at the Jefferies 2016 London Healthcare Conference in London, UK on
Thursday, November 17, 2016, at 4:00 pm GMT.
Susanna Mesa, Senior Vice President, Strategy, will host investor meetings
during Citi's 2016 Global Healthcare Conference in New York, NY on Wednesday,
December 7, 2016.
A live audio webcast of the Jefferies Conference presentation will be available
on the Investor Relations section of the Company's website, http://www.dbv-
technologies.com/en/investor-relations. A replay will also be available 48 hours
after the event.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY
as well as New Jersey, CT. Company shares are traded on segment B of Euronext
Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and
traded on the Nasdaq Global Select Market in the form of American Depositary
Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For
more information on DBV Technologies, please visit our website: www.dbv-
technologies.com
Forward Looking Statements
This press release contains forward-looking statements, including statements
reflecting management's expectations regarding the clinical development of
Viaskin Peanut, the safety, efficacy and durability of Viaskin Peanut for the
treatment of peanut allergy, and the commercial potential of Viaskin Peanut.
These forward-looking statements are not promises or guarantees and involve
substantial risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected herein include
uncertainties associated generally with research and development, clinical
trials and related regulatory reviews and approvals, the risk that historical
clinical trial results may not be predictive of future trial results and the
risk that Viaskin Peanut may not receive regulatory approval notwithstanding the
results of clinical trials. A further list and description of these risks,
uncertainties and other risks can be found in the Company's regulatory filings
with the French Autorité des Marchés Financiers, the Company's Securities and
Exchange Commission filings and reports, including in the Company's Annual
Report on Form 20-F for the year ended December 31, 2015 and future filings and
reports by the Company. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date hereof. DBV Technologies undertakes no obligation to update or revise
the information contained in this Press Release, whether as a result of new
information, future events or circumstances or otherwise.
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contact
Erinn White, Centron PR
+1-646-722-8822
ewhite(at)centronpr.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF version:
http://hugin.info/156437/R/2055675/769837.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.11.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 506057
Anzahl Zeichen: 5524
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies to Attend Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
